About the BooK: Cardiometabolic Medicine 2022
“Cardiometabolic Medicine 2022” is to curb the growing menace of cardiometabolic
diseases by disseminating the current preventing and therapeutic strategies to
improve the cardiometabolic outcomes. Most of the cardiometabolic diseases like
obesity, diabetes, hypertension, atherosclerotic, cardiovascular disease etc.
commonly co-exists and produces multiple co-morbidities which are beyond the
reach of a physician or single specialist to comprehensively evaluate and treat
them and therefore requires a cohesive effort of several specialties. Salient
Feature Dedicated section on atherosclerotic cardiovascular disease (ASCVD),
emerging drugs vericiguat and omecamtiv mecarbil, new approved weapons for heart
failure like sacubitril valsartan and SGLT2 inhibitors. Dedicated section with
focus on Obesity, Lipid